Cardiac Toxicity Study of C70 Fullerenol Nanoparticles in Mice

doi:10.7517/j.issn.1674-0475.180105

Imaging Science and Photochemistry ›› 2018, Vol. 36 ›› Issue (4): 324-330.DOI: 10.7517/j.issn.1674-0475.180105

Previous Articles Next Articles

Cardiac Toxicity Study of C₇₀ Fullerenol Nanoparticles in Mice

GUO Jun^1,2, ZHOU Yue^2,3, YANG Dongzhi¹, ZHEN Mingming^2,3, XU Hui², WANG Chunru^2,3

1. Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, Jiangsu, P. R. China;
2. Key Laboratory of Molecular Nanostructure and Nanotechnology, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, P. R. China;
3. University of Chinese Academy of Sciences, Beijing 100049, P. R. China

Received:2018-01-18 Revised:2018-03-02 Online:2018-07-15 Published:2018-07-15

Abstract

Abstract: The cardiac effect of C₇₀ fullerenol nanoparticles (C₇₀-OH NPs) was studied in mice. After treated with the C₇₀-OH fullerene of normal therapeutic dose, behavioral observation, cardiac coefficient, blood biochemical changes, pathological changes and tissue transmission of mice were detected. The results showed that the commonly used small molecule vascular blocker combretastatin disodium phosphate (CA4P) significantly damaged the myocardium, while C₇₀-OH did not show significant cardiotoxicity.

Key words: C₇₀ fullerenol, pathological changes, tissue transmission, cardiac toxicity

GUO Jun, ZHOU Yue, YANG Dongzhi, ZHEN Mingming, XU Hui, WANG Chunru. Cardiac Toxicity Study of C₇₀ Fullerenol Nanoparticles in Mice[J]. Imaging Science and Photochemistry, 2018, 36(4): 324-330.

References

[1] Friedman S H, DeCamp D L, Sijbesma R P, Srdanov G, Wud F, Kenyon G L. Inhibition of the HIV-1 protease by fullerene derivatives:model building studies and experimental verification[J]. Journal of the American Chemical Society, 1993, 115(15):6506-6509.
[2] Lyon D Y, Adams L K, Falkner J C, Alvarezt P J. Antibacterial activity of fullerene water suspensions:effects of preparation method and particle size[J]. Environmental Science & Technology, 2006, 40(14):4360-4366.
[3] Li J, Guan M R, Wang T S, Zhen M M, Zhao F W, Shu C Y, Wang C R. Gd@C₈₂-(ethylenediamine)₈ nanoparticle:a new high-efficiency water-soluble ROS scavenger[J]. ACS Applied Materials & Interfaces, 2016, 8(39):25770-25776.
[4] Zhou Y, Li J, Ma H J, Zhen M M, Guo J, Wang L P, Jiang L, Shu C Y, Wang C R. Biocompatible
[60] /
[70] fullerenols:potent defense against oxidative injury induced by reduplicative chemotherapy[J]. ACS Applied Materials & Interfaces, 2017, 9(41):35539-35547.
[5] Zhang Y, Shu C Y, Zhen M M, Li J, Yu T, Jiang W, Li X, Deng R J, Zhou Y, Wang C R. A novel bone marrow targeted gadofullerene agent protect against oxidative injury in chemotherapy[J]. Science China Materials, 2017, 60(9):866-880.
[6] Guan M R, Ge J C, Wu J Y, Zhang G Q, Chen D Q, Zhang W, Zhang Y, Zou T J, Zhen M M, Wang C R, Chu T W, Hao X J, Shu C Y. Fullerene/photosensitizer nanovesicles as highly efficient and clearable phototheranostics with enhanced tumor accumulation for cancer therapy[J]. Biomaterials, 2016, 103:75-85.
[7] Zhou Y, Deng R J, Zhen M M, Li J, Guan M R, Jia W, Li X, Zhang Y, Yu T, Zou T J, Lu Z G, Guo J, Sun L, Shu C Y, Wang C R. Amino acid functionalized gadofullerene nanoparticles with superior antitumor activity via destruction of tumor vasculature in vivo[J]. Biomaterials, 2017, 133:107-118.
[8] Chen C Y, Xing G M, Wang J X, Zhao Y L, Li B, Tang J, Jia G, Wang T C, Sun J, Xing L, Yuan H, Gao Y X, Meng H, Chen Z, Zhao F, Chai Z F, Fang X H. Multihydroxylated[Gd@C₈₂(OH)₂₂]_<i>n nanoparticles:antineoplastic activity of high efficiency and low toxicity[J]. Nano Letters, 2005, 5(10):2050-2057.
[9] Zhen M M, Shu C Y, Li J, Zhang G Q, Wang T S, Luo Y, Zou T J, Deng R J, Fang F, Lei H, Wang C R, Bai C L. A highly efficient and tumor vascular-targeting therapeutic technique with size-expansible gadofullerene nanocrystals[J]. Science China Materials, 2015, 58(10):799-810.
[10] Siemann D W, Bibby M C, Dark G G, Dicker A P, Eskens F A, Horsman M R, Marmé D, Lorusso P M. Differentiation and definition of vascular-targeted therapies[J]. Clinical Cancer Research, 2005, 11:416-420.
[11] Dowlati A, Robertson K, Cooney M, Petros WP, Stratford M, Jesberger J, Rafie N, Overmoyer B, Makkar V, Stambler B, Taylor A, Waas J, Lewin JS, McCrae K R, Remick SC. A phase Ⅰ pharmacokinetic and translational study of the novel vascular targeting agent combretasta-tin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer[J]. Cancer Research, 2002, 62(12):3408-3416.
[12] Wang C, Bai Y, Li H, Liao R, Li J, Zhang H, Zhang X, Zhang S, Yang S T, Chang XL. Surface modification-mediated biodistribution of ¹³C-fullerene C₆₀ in vivo[J]. Particle and Fibre Toxicology, 2016, 13:14.

Cardiac Toxicity Study of C₇₀ Fullerenol Nanoparticles in Mice

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics

Comments